Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms. Over-activation of the complement system, a crucial part of innate immunity, plays an important role in DKD. We aimed to...

Full description

Bibliographic Details
Main Authors: Dong-Yuan Chang, Xiao-Qian Li, Min Chen, Ming-Hui Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Pharmacology
Subjects:
sodium glucose co-transport-2 (SGLT2) inhibitors
dapagliflozin
diabetic kidney disease
complement over-activation
complement receptor type 1-related protein y (Crry)
hypoxia inducible factor-1α (HIF-1 α)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.729334/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.729334/full

Similar Items